HIP

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, February 29, 2024

The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.

Key Points: 
  • The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects initial data to be shared in the first half of 2024.
  • Non-GAAP research and development expense in 2023 excludes an expense related to the impairment of certain lab equipment and leasehold improvements, primarily due to the portfolio prioritization in the fourth quarter of 2023.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Westlake Corporation Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024

Excluding the Identified Items, fourth quarter of 2023 net income attributable to Westlake was $93 million and EBITDA was $390 million.

Key Points: 
  • Excluding the Identified Items, fourth quarter of 2023 net income attributable to Westlake was $93 million and EBITDA was $390 million.
  • Fourth quarter 2023 net income attributable to Westlake of $93 million decreased by $192 million sequentially as compared to the third quarter of 2023.
  • EBITDA of $390 million for the fourth quarter of 2023 decreased by $229 million compared to fourth quarter 2022 EBITDA of $619 million.
  • Fourth quarter 2023 EBITDA decreased by $292 million compared to third quarter 2023 EBITDA of $682 million.

Trive-backed Kittyhawk Acquires Stack HIP from Stack Metallurgical Group

Retrieved on: 
Thursday, March 7, 2024

GARDEN GROVE, Calif. and DALLAS, March 7, 2024 /PRNewswire/ -- Kittyhawk, Inc. ("Kittyhawk" or the "Company"), backed by the Dallas-based private equity firm Trive Capital ("Trive"), is pleased to announce that it has acquired Stack HIP, LLC ("Stack HIP") from Stack Metallurgical Group ("SMG").

Key Points: 
  • GARDEN GROVE, Calif. and DALLAS, March 7, 2024 /PRNewswire/ -- Kittyhawk, Inc. ("Kittyhawk" or the "Company"), backed by the Dallas-based private equity firm Trive Capital ("Trive"), is pleased to announce that it has acquired Stack HIP, LLC ("Stack HIP") from Stack Metallurgical Group ("SMG").
  • Operating from its facility in Albany, OR, Stack HIP is a market leader of HIP services to aerospace, defense, and medical customers.
  • Stack HIP possesses the largest high-pressure HIP vessels in North America, enabling the processing of the biggest and most complex castings and additively manufactured metallic parts.
  • "We're excited to welcome Stack HIP customers, employees, and suppliers into the Kittyhawk family," said Brandon Creason, President of Kittyhawk.

Semperis to Host its Annual Hybrid Identity Protection Conference in New Orleans on November 13-14

Retrieved on: 
Wednesday, March 6, 2024

HOBOKEN, N.J., March 6, 2024 /PRNewswire-PRWeb/ -- Semperis, a pioneer in identity-driven cyber resilience, today announced that its annual (Hybrid Identity Protection Conference (HIP Conf), will take place November 13-14 in New Orlean at Mardi Gras World. HIP Conf 24 brings together the world's foremost Active Directory (AD), Entra ID, and Okta security experts, working at the intersection of identity and security to deliver technical presentations, participate in panel discussions and network with attendees.

Key Points: 
  • Award-Winning Conference Will Host the World's Foremost Active Directory, Entra ID, and Okta Security Experts
    HOBOKEN, N.J., March 6, 2024 /PRNewswire-PRWeb/ -- Semperis , a pioneer in identity-driven cyber resilience, today announced that its annual (Hybrid Identity Protection Conference (HIP Conf) , will take place November 13-14 in New Orlean at Mardi Gras World.
  • "Cyber threat actors no longer break in, they log in," said Mickey Bresman, CEO, Semperis.
  • In 2017, I created the HIP Conf for IAM professionals to share information about the importance of securing hybrid AD environments and to learn from one another.
  • ), a Partner at KKR and former Director of the CIA, spoke at last year's conference in New York.

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Retrieved on: 
Tuesday, February 13, 2024

SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.” The paper evaluated a transplant of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells into a fully immunocompetent, diabetic non-human primate (NHP). These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets). The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.

Key Points: 
  • These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets).
  • The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.
  • This publication, along with the ongoing IST, will provide invaluable insights toward our stem cell derived product candidate, SC451.
  • It was thus demonstrated that the tightly controlled blood glucose levels and insulin independence was entirely due to well-functioning HIP p-islets.

Second Quintus Hot Isostatic Press on Order for Wallwork Group Bury Centre

Retrieved on: 
Thursday, February 1, 2024

VÄSTERÅS, Sweden, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Less than six months after opening, Wallwork Heat Treatment Ltd.'s Hot Isostatic Pressing (HIP) Centre is preparing to accommodate its second HIP system from Quintus Technologies. Record customer interest in its expanded thermal processing capabilities has prompted the company to order a second press, the QIH 173L M URC®, the same model that inaugurated the HIP Centre when it opened in September 2023.

Key Points: 
  • VÄSTERÅS, Sweden, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Less than six months after opening, Wallwork Heat Treatment Ltd.'s Hot Isostatic Pressing (HIP) Centre is preparing to accommodate its second HIP system from Quintus Technologies .
  • --Simeon Collins, Wallwork Holdings
    Much of the interest stems from burgeoning opportunities in additive manufacturing (AM) and encapsulation, according to Wallwork Holdings Director Simeon Collins.
  • Hot Isostatic Pressing plays a pivotal role in the production of AM parts made from metal powders.
  • The decision to purchase a second press from Quintus was a logical move given the success of its first system.

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 11, 2023

SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP) technology were presented at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

Key Points: 
  • “HIP-modified allogeneic CAR T cells remain well-tolerated in preclinical models.
  • CD22 HIP CAR T cells were well tolerated with no signs of graft-versus-host disease (GvHD).
  • Sana submitted the investigational new drug (IND) application and intends to begin human testing of SC262 in early 2024.
  • Additionally, these GPRC5D CAR T cells controlled multiple myeloma tumor cells both in vitro and in vivo, demonstrating efficacy that is on par with clinical benchmark GPRC5D CAR T cells.

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

Retrieved on: 
Friday, December 1, 2023

SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL).

Key Points: 
  • SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL).
  • ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma.
  • Treatment in this dose escalation study is ongoing, and the company expects to present more data from this study at a later date in an appropriate venue.
  • “These are the first clinical data demonstrating that our HIP technology can engineer allogeneic cells to evade adaptive and innate immune detection and rejection in the context of an intact immune system, overcoming the key challenge in unlocking the potential of allogeneic cells,” said Gary Meininger, MD, Sana’s Chief Medical Officer.

Great Day Improvements Acquires Home Performance Alliance®, Expanding Its Offerings to Florida Market

Retrieved on: 
Friday, December 22, 2023

HPA supplies homeowners’ solutions to their extreme weather conditions and remodeling needs across window replacement, bath remodels and a new offering for Great Day Improvements with high-performance roofing solutions.

Key Points: 
  • HPA supplies homeowners’ solutions to their extreme weather conditions and remodeling needs across window replacement, bath remodels and a new offering for Great Day Improvements with high-performance roofing solutions.
  • The strategic expansion reflects Great Day Improvements’ commitment to providing exceptional home improvement solutions suitable for all environments.
  • With Great Day Improvements built on a foundation of entrepreneurial spirit, they share our values and business model,” said Michael Hoy, CEO of Great Day Improvements.
  • Carolyn Resar, EVP of Integration at Great Day Improvements, will oversee the seamless onboarding of HPA, reporting to Drew Weinfurtner, president and COO.

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

Retrieved on: 
Friday, November 17, 2023

SEATTLE, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, and Uppsala University Hospital in Sweden today announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to initiate an investigator-sponsored, first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes.

Key Points: 
  • The goal of UP421 treatment is to provide proof of concept for transplanting functional islet cells without immunosuppression.
  • UP421 is engineered using Sana’s hypoimmune platform modifications with the goal of evading both allogeneic and autoimmune rejection.
  • Insights from this study may inform development of Sana’s SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
  • “Islet cell transplantation has shown curative potential for patients with type 1 diabetes, but the need for concurrent immunosuppression has led to side effects, limited efficacy, and decreased utilization.